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Objective: This trial was conducted to determine if covered stents offer a patency advantage over bare-metal stents in the
treatment of aortoiliac arterial occlusive disease.
Methods: The Covered Versus Balloon Expandable Stent Trial (COBEST), a prospective, multicenter, randomized
controlled trial, was performed involving 168 iliac arteries in 125 patients with severe aortoiliac occlusive disease who
were randomly assigned to receive a covered balloon-expandable stent or bare-metal stent. Patient demographic data,
clinical signs and symptoms, TransAtlantic Inter-Society Consensus (TASC) classification, and preprocedure and
postprocedure ankle-brachial index measurements were recorded. The primary end points included freedom from binary
restenosis and stent occlusion of the treated area, as determined by ultrasound imaging or quantitative visual angiogra-
phy, or both. Postprocedural follow-up was at 1, 6, 12, and 18 months.
Results: Aortoiliac lesions treated with a covered stent were significantly more likely to remain free from binary restenosis
than those that were treated with a bare-metal stent (hazard ratio [HR], 0.35; 95% confidence interval (CI), 0.15-0.82;
P  .02). Freedom from occlusion was also higher in lesions treated with covered stents than in those treated with a
bare-metal stent (HR, 0.28; 95% CI, 0.07-1.09); however, this did not reach statistical significance (P  .07). Subgroup
analyses demonstrated a significant difference in freedom from binary restenosis for covered stents in TASC C and D
lesions compared with a bare stent (HR, 0.136; 95% CI, 0.042-0.442). This difference was not demonstrated for TASC
B lesions (HR, 0.748; 95% CI, 0.235-2.386).
Conclusions: COBEST demonstrates covered and bare-metal stents produce similar and acceptable results for TASC B
lesions. However, covered stents perform better for TASC C and D lesions than bare stents in longer-term patency and
clinical outcome. (J Vasc Surg 2011;54:1561-70.)
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CAortoiliac arterial occlusive disease is frequently en-
countered in the management of lower limb vascular insuf-
ficiency. Surgical reconstruction of the aortoiliac segment
was initially performed using thromboendarterectomy1;
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December 20111562 Mwipatayi et alAlthough a laparoscopic approach may decrease this mor-
tality and morbidity, this technique has yet to become
common place.8
Currently, the decision to perform an endovascular
procedure or open surgical bypass depends on various
factors, most importantly, the severity and anatomic distri-
bution of disease. The TransAtlantic Inter-Society Consen-
sus (TASC) I and II working group published a consensus
of recommendations for management of peripheral arterial
disease.9,10 The recommendation for patients with focal or
short lesions (ie, TASC A and TASC B lesions) is endovas-
cular intervention with an evidence basis suggesting long-
term patency rates close to 80% at 2 years and 60% at 5
years.11,12 Lower patency rates with TASC C and D lesions
led to the recommendation for an open surgical approach,
except in patients deemed to be high-risk.
The use of covered stents to treat aortoiliac occlusive
disease has been proposed as a method to reduce intimal
hyperplasia and improve patency rates.13-15 Although the
results of numerous reports are promising, present evidence
is insufficient to support their widespread application. Cur-
rently, covered stent use is largely reserved for the treat-
ment of aneurysms, ruptures, and arteriovenous fistulas.16-18
No published randomized controlled trials (RCTs) to date
have compared the efficacy of covered stents vs bare-metal
stents (BMSs) for aortoiliac occlusive disease. We hypoth-
esized that via intimal exclusion, covered stents will provide
a patency advantage and improved clinical outcome in
advanced iliac occlusive disease compared with BMS.
METHODS
Study design. The Covered Versus Balloon Expand-
able Stent Trial (COBEST) was a prospective, multicenter,
RCT (registration number: ISRCTN89458845) compar-
ing the use of the Advanta V12 balloon-expandable cov-
ered stent (Atrium Medical Corp, Hudson, NH) with
commercially available bare-metal stents (BMS) in patients
with aortoiliac occlusive disease. The study was conducted
between January 2006 and December 2008 with 13 phy-
sicians (11 vascular surgeons and 2 interventional radiolo-
gists) at eight major centers across Australia. The study
design allowed an assessment of the safety and efficacy of
covered stents vs BMSs in the treatment of hemodyna-
mically significant aortoiliac occlusive disease. In particular,
COBEST aimed to determine if the theoretical advantage
of covered stents resulted in clinical improvements.
The institutional review board and ethics committees at
each hospital approved the study protocol, and written
informed consent was obtained from all patients before
enrollment. The criterion for study entry and exclusion are
listed in Table I.
Study end points. The primary study end point was
the rate of binary restenosis (defined by50% reduction in
lumen diameter) and freedom from stent occlusion at 18
months. These were determined by duplex ultrasound
(DUS) imaging of the aortoiliac segment, computed to-
mography angiography (CTA), or catheter biplane digital
subtraction angiography (DSA). Patients were assessed ilinically with an ankle-brachial index (ABI) and aortoiliac
rterial DUS at intervals of 1, 6, 12, and 18 months. If the
US scan was inconclusive, a CTA or DSA, or both, were
erformed using a prespecified protocol to determine if the
rimary end point had been achieved.
The secondary end points were determined anato-
ically, clinically, and hemodynamically. Anatomic end
oints included stent patency, as assessed by the TASC B,
, and D classification, stent integrity, and target vessel
evascularization (TVR), defined as any repeat percutane-
us intervention or surgical bypass of any segment of the
arget vessel. The target vessel was defined as the entire
ortoiliac vessel proximal and distal to the target lesion.
VR was typically driven by clinical evidence of symptoms
r positive stress-induced significant symptoms (treadmill
xercise ABI).
The clinical end points were major amputation above
he ankle and major adverse events resulting in patient
ospitalization or prolongation of existing hospitalization,
ignificant physical disability, or death. The hemodynamic
nd point was a change in ABI between baseline and
easurements at 1, 6, 12, and 18 months.
Randomization. Eligible patients were randomized
o receive a covered stent or a BMS by an online computer-
zed randomization program (https://io.atriummed.com/
obest/default.aspx). Unstratified randomization was
sed to randomize patients in a 1:1 ratio with a minimiza-
ion algorithm to allow balanced allocation of participants
cross intervention groups. All randomized patients were
able I. Inclusion and exclusion criteria for the Covered
ersus Balloon Expandable Stent study
nclusion criteria
Men and women aged 18 years
Informed consent obtained
Evidence of TASC B, C, or D lesions
Hemodynamically significant dissections and recurrent stenosis
after angioplasty
xclusion criteria
Life expectancy 12 months (patients had to be followed up
for at least 18 months)
Uncontrolled hypertension
TASC A lesion
Pregnant women or women of childbearing potential who
were not using an effective method of contraception
Prior enrollment in this trial, or a patient who had had any
procedure performed at the aortoiliac level
Extensive common femoral artery disease or multiple groin
procedures
Contraindication to aspirin or clopidogrel usage
Occluded superficial and profunda femoral arteries
Mental condition rendering the individual unable to
understand the nature, scope and possible consequences of the
study, or a language barrier preventing the individual from
providing informed consent
Uncooperative attitude or potential for noncompliance with
the protocol requirements, making study participation
impractical
ASC, TransAtlantic Inter-Society Consensus.rrevocably included in the study, regardless of eligibility or
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Volume 54, Number 6 Mwipatayi et al 1563if they received the allocated treatment, and were moni-
tored for 18 months. A subgroup of patients had bilateral
lesions and each side of the iliac artery disease (left or right)
was randomized in these patients rather than the patient
per se.
Stents. The investigational devices consisted of the
Advanta V12 covered stent and commercially available
BMSs. The Advanta V12 is encapsulated with expanded
polytetrafluroethylene (ePTFE), premounted on an Aner-
tia noncompliant balloon (Atrium Medical Corp), and
compatible with a 6F to 7F sheath. Stents were sized
perioperatively, with covered and BMS oversized by 1 mm
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December 20111564 Mwipatayi et alMedical therapy. All patients received aspirin (100-
150mg daily) indefinitely and clopidogrel (75mg daily) for
a minimum of 1 month after the intervention. A 300-mg
loading dose of clopidogrel was given during or after the
intervention.
Study procedures. Access to the iliac lesion was
achieved at the investigator’s discretion via an antegrade
approach from the contralateral femoral artery with the use
of a dedicated 6F or 7F “cross-over” sheath or via a
retrograde (ipsilateral) approach. A brachial approach was
used at the discretion and experience of the investigator
using a Shuttle sheath (Cook Medical, Bloomington, Ind).
After sheath placement, a heparin bolus (3000-5000 units)
was administered intravenously.
DSA was performed to assess and confirm the DUS
imaging or CTA findings. The patency status of the ipsilat-
eral femoral, popliteal, and infrapopliteal arteries was doc-
umented. After the target lesion was successfully crossed
with a hydrophilic 0.018-inch or 0.035-inch wire, patients
were randomized and received a covered balloon-expandable
stent or a BMS.
At baseline and each follow-up, all patients were strat-
ified by symptoms according to categories outlined previ-
Table II. Characteristics of the study patients at baseline
according to treatment groups
Characteristica
V12 stent Bare stent
(n  83) (n  85)
Patients, No. 62 63
Age, years 65.34  1.43 67.21  1.29
Male sex 67.7 57.1
Race
White 96.8 95.2
Aboriginal 1.6 1.6
Asian 1.6 3.2
Side of lesion
Left 59.0 42.4
Right 39.8 56.5
Central 1.2 1.1
Rutherford-Becker
Category 1 3.2 4.8
Category 2 27.4 30.2
Category 3 40.3 50.8
Category 4 24.2 12.7
Category 5 4.8 1.6
Risk factors
Diabetes 24.2 28.6
Hypertension 56.5 71.4
Smoking 59.7 58.7
Hyperlipidemia 41.9 46.0
Chronic renal failure 3.2 3.2
COAD 9.7 9.5
Coronary artery disease 37.1 38.1
Hypercoagulable states 6.5 3.2
Pre-op antiplatelets 88.7 93.7
Aspirin 87.1 84.1
Clopidogrel 9.7 19.0
COAD, Chronic obstructive airway disease.
aContinuous data are expressed as mean  standard error of the mean, and
categoric data as number or percentage.ously by Rutherford et al.19 The status of the runoff vessels sas determined using an objective scoring system.19 The
uperficial and deep femoral arteries, which are the runoff
essels for iliac artery procedures, were evaluated by the
resence of an occlusion or stenosis, or if they were patent.
Mandatory clinical evaluations combined with mea-
urement of ABIs were performed at each postprocedural
ollow-up at 1, 6, 12, and 18 months. DUS imaging of the
ortoiliac segment was also performed at each visit. Binary
estenosis was defined by a doubling of peak systolic veloc-
ties (PSV) across a lesion or a PSV 300 cm/s with
onophasic Doppler waveforms in the distal common
emoral artery.20-22 Medical events, hospitalizations, access
nterventions, and adverse events were documented.
Statistical analysis. Sample size was calculated using
he method proposed by Armitage et al.23 Because there
as been no previous RCT comparison between groups
ith the two types of stent, an initial limit of noninferiority
etween the two groups was estimated to be 10% of the
rue population restenosis rate, which we assumed to be 6%.
ith power set at 80% and  set at 5% (on a two-sided test),
he number of iliac arteries required was calculated to be 70
n each group, giving a total of 140 limbs. To compensate
or patients lost to follow-up, we included an additional 14
imbs. Thus, the total target sample size was calculated to
e at least 154 limbs. One patient did not receive the
llocated treatment (cross-over treatment). This was a con-
cious decision by the surgeon because the randomized
able III. Clinical and radiologic characteristics of the
tudy patients at baseline according to treatment groups
haracteristica
V12 stent Bare stent
(n  83) (n  85)
reoperative assessment
esting ABI (side of lesion) 0.65  0.03 0.63  0.03
No. 75 78
uplex scan
Performed 62 (74.7) 65 (76.5)
50% stenosis 87.1 81.5
Occlusion 12.9 18.5
ngiogram
Performed 67 (80.7) 73 (85.9)
TASC B 50.7 72.6
TASC C 34.3 20.5
TASC D 14.9 6.8
T angiogram
Performed 32 (38.6) 36 (42.4)
TASC B 56.3 63.9
TASC C 31.3 30.6
TASC D 12.5 5.6
unoff
Performed 74 (89.1) 73 (85.9)
0 0 1.4
1 12.2 5.5
2 20.3 21.9
3 23.0 37.0
4 44.6 34.2
BI, Ankle-brachial index; TASC, TransAtlantic Inter-Society Consensus.
Data are number (%) or mean  standard error of the mean.tent was not available.
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ment, we undertook two main analyses. An intention-to-
treat analysis was performed for all baseline and primary end
point data for all randomized patients irrespective of
whether the patient received the randomized study device
or the patient’s compliance with the study protocol. A
per-protocol analysis was performed for all subgroup anal-
yses and secondary end point data because the one cross-
over patient’s data did not create any difference between
the intention-to-treat analysis and the per-protocol analy-
sis.
Baseline characteristics of the two groups were de-
scribed using means and standard errors (SE) for continu-
ous data and proportions for qualitative variables. Freedom
from binary restenosis and freedom from stent occlusion at
1, 6, 12, and 18 months were analyzed with the use of
Kaplan-Meier survival estimates. Cox proportional hazards
models were used to determine if differences between the
estimates were significant after establishing the requisite
proportional hazards assumptions were met. Alternative
end points, occlusion, and binary restenosis at 18 months,
were analyzed using logistic regression.
Subgroup analyses of both restenosis end points were
performed by testing the interaction of subgroup and ran-
domized treatment. There were insufficient numbers of
vessels with an occlusion for subgroup analysis to be per-
formed. Logistic regression was also used to investigate the
differences in proportions of patients with limb amputation
between the two randomized groups. Results are reported
as hazard ratios (HR) or odds ratios (OR) with 95% confi-
Fig 2. Kaplan-Meier curves are shown for freedom from
sandwich variance estimate method (Lin and Wei) was us
.0243). CI, Confidence interval; HR, hazard ratio.dence intervals (CI). dWhen two iliac arteries from the same patient were
andomized, it was necessary to recognize that the vessels
ere genetically identical and therefore the outcomes
ould be correlated. To adjust for the intracluster correla-
ion, robust sandwich estimators, as proposed by Lin and
ei (1989),24 were used to produce cluster adjusted SEs
nd P values for all logistic regression and survival analyses.
nalysis of the change in ABI indexes and TVR over time
as performed using a hierarchic longitudinal mixed-models
nalysis. The interaction between randomized treatment
nd time was used to determine if there were differences
n the treatment slopes over time for the linear ABI model.
he small number of TVR cases precluded investigation of
he interaction in the logistic model.
All hypotheses tests were performed using two-sided
ests, and the critical value for statistical significance was set
t a value of P .05. Analyses were conducted using PASW
8 (SPSS, Chicago, Ill), SAS 9.2 (SAS Institute Inc, Cary,
C), and Stata 11 (StataCorp LP, College Station, Tex)
tatistical software.
ESULTS
The trial recruited 125 patients (168 individual iliac
rteries). Randomization assigned 83 vessels to receive a
overed stent and 85 to receive a BMS (Fig 1). Patients
ere assessed at the prespecified intervals for 18 months.
ne patient in the covered-stent group and eight in the
MS group were lost to follow-up.
At baseline, demographic and clinical characteristics
ere similar between the two groups, with no significant
ry restenosis for the intention-to-treat population. The
determine the log-rank test adjusted for clustering (Pbina
ed toifferences in the frequency of atherothrombotic risk fac-
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Most patients in both groups were already receiving anti-
platelet agents, and only three patients were taking oral
anticoagulation medications (Table II). In the BMS group,
Palmaz Genesis, Express LD, Assurant Cobalt, and Peiron
stents were used predominantly.
Preoperative imaging demonstrated 72.6% in the BMS
group had TASC B lesions vs 50.7% in the covered-stent
group (Table III).
Procedural complications included hemorrhage, flow-
limiting dissection, lymph leak, and seroma formation, with
no statistical significance between the groups. Intravascular
anticoagulation was administered to 97.6% of patients dur-
ing the procedure. No conversions to open aortoiliac sur-
gery during the perioperative period were reported. Proce-
dural success, defined as30% residual stenosis during the
angiographic intervention, was achieved in 100% of cases in
both groups.
Primary outcome. Aortoiliac lesions treated with a
covered stent were significantly more likely to remain free
from binary restenosis at 18 months than those that were
treated with a BMS (HR, 0.35; 95% CI, 0.15-0.82; P 
.02). Binary restenosis was documented in 8 arteries in the
covered-stent group and in 20 in the BMS group (Fig 2).
Complete occlusions of the stented lesion during the
follow-up period occurred in 3 patients in the covered-stent
group and in 10 patients in the BMS group; however, this
difference was not statistically significant (HR, 0.28; 95%
CI, 0.07-1.09; P  .07; Fig 3).
Subgroup analyses. The subgroup analysis specifically
looked at freedom from binary restenosis according to the
Fig 3. Kaplan-Meier curves are shown for freedom fro
sandwich variance estimate method was used to determi
Confidence interval; HR, hazard ratio.initially designated TASC lesions. A significant interaction bas found between the TASC classification and the stent
ype for binary restenosis at 18 months (P .03). None of
he factors investigated were significant (Fig 4). This study
as not powered to investigate interactions; hence, further
esearch is required to confirm these results. The Kaplan-
eier survival estimates showed a statistically significant
nt occlusion for the intention-to-treat population. The
e log-rank test adjusted for clustering (P  .0874). CI,
ig 4. Odds ratios of 18-month restenosis of 50% in selected
atient subgroups. For most of the variables, the 95% confidence
nterval crosses the line of identity, indicating lack of statistical
ignificance. The probability values for interaction indicate that
nly TransAtlantic Inter-Society Consensus (TASC) variables in-
eracted on the level of statistical significance with the treatment
odality.m ste
ne thenefit when covered stents were used in TASC C and D
w
9
C
.0056
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0.442; Fig 5; Appendix Fig, online only). However, this
significant difference in freedom from binary restenosis was
not demonstrated for TASC B lesions (HR, 0.748; 95% CI,
Fig 5. Kaplan-Meier curves are shown for freedom from
TransAtlantic Inter-Society Consensus (TASC) C/D g
determine the log-rank test adjusted for clustering (P 
Fig 6. Kaplan-Meier curves are shown for freedom from
TransAtlantic Inter-Society Consensus (TASC) B group
patients with TASC B lesion. CI, Confidence interval; H0.235-2.386; Fig 6). lThe 44 patients who had bilateral iliac artery stenting
ere randomized to receive 43 covered stents (SE, 0.473;
5% CI, 16.399-18.252) and 45 BMSs (SE, 0.970; 95%
I, 12.304-16.106). The same stent was allocated to both
ry restenosis for the type of stent used according to the
The sandwich variance estimate method was used to
). CI, Confidence interval; HR, hazard ratio.
ry restenosis for the type of stent used according to the
re is no statistical difference between the two stents in
zard ratio.bina
roup.bina
. Theimbs in 20 of the 44 patients. The overall freedom from
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less restenosis in covered stents compared with the BMSs
(HR, 0.14; 95% CI, 0.03-0.61; P .009). The interaction
of TASC group and randomized stent was not significant
(P  .23).
Secondary outcomes. ABI measurements during the
follow-up period were not significantly different between
the two groups at 1 and 6 months. However, the difference
became statistically significant at 12months (P .014) and
had marginal significance at 18 months (P. 06), suggest-
ing long-term improvement in ABIs in the covered-stent
group (Table IV).
TVR during the study period demonstrated that there
was less reintervention in the covered-stent group com-
pared with the BMS group (OR, 21; 95% CI, 0.07-0.64;
P  .006). Most of the reinterventions were performed at
12 and 18 months (Fig 7). Three patients from the BMS
group underwent aortobifemoral bypass grafting.
Four amputations were performed during the study
period. Two patients with covered stents had below knee
amputation at 18 months, which was likely related to
uncontrollable diabetes mellitus and progression of infra-
genicular arterial disease. Two patients with BMSs had
above knee amputations at 18 months due to a combina-
tion of factors. The difference between the two groups was
not statistically significant (OR, 1.02; 95% CI, 0.089-
11.73; P  .984).
A left brachial artery approach was used in 10 patients,
with 1 patient requiring the use of the Outback LTD
re-entry catheter (Cordis Corp), with a successful outcome.
None of these patients had any major complications (no
cerebral ischemic event or vessel perforation) related to the
approach used. Multiple associated procedures were per-
formed during iliac artery stenting: femoropopliteal bypass
graft in five patients, common femoral artery endarterec-
tomy in four, and superficial femoral artery stenting in four.
External iliac artery stenting was performed in 14 patients,
with successful outcome at 12 and 18 months.
DISCUSSION
The COBEST trial is the first RCT to compare covered
stents and BMSs in the management of aortoiliac occlusive
disease. Previous studies have compared different types
of BMSs deployed in iliac arteries and failed to demons-
Table IV. Resting ankle-brachial index (ABI) on side of
the lesion
Resting
ABI
V12 stent Bare stent
PNo. Mean  SEM No. Mean  SEM
Baseline 75 .65  .03 78 .63  .03 .639
1 month 71 .91  .03 72 .91  .03 .927
6 months 73 .89  .02 74 .88  .03 .653
12 months 75 .94  .02 79 .85  .03 .014
18 months 70 .94  .02 73 .86  .03 .07
SEM, Standard error of the mean.trate any significant differences in technical success and iollow-up outcomes.25-27 The only published randomized
tudy comparing primary angioplasty, followed by selective
r primary stent placement in patients with iliac artery
bstructive disease, is the Dutch Iliac Stent Trial (DIST).
he short-term and long-term DIST results indicated that
elective stent placement should be considered as the treat-
ent of choice.11
Angioplasty is a less invasive alternative treatment to
pen bypass surgery and proven efficacy for the treatment
f patients with focal iliac artery stenosis. The procedural
echnical success rate has improved significantly (up to
5%), especially when adjunctive stent placement is used.
atency rates of 80% to 90% after 5 years have been re-
orted for short iliac stenoses, which is comparable with
atency results for open surgery.28,29 For complex, multi-
ocal, or totally occluded atherosclerotic segments of iliac
rteries (C and D lesions), TASC recommends surgery as
he procedure of choice.10
Since their first applications by Dotter, endovascular
etallic stent placement has been widely used for the
reatment of patients with aortoiliac occlusive disease.30,31
orwerk et al32,33 reported 4-year patency rates of 78% and
2% for primary and secondary stenting procedures, respec-
ively, in 100 patients. Cikrit et al34 reported a 5-year
atency rate of 63% in 38 limbs that were treated by Palmaz
tent placement, whereas Palmaz et al25 initially reported a
2% patency rate at 9 months. Primary 4-year patency rates
s high as 86% were recently reported.25,31
Covered stents are able to exclude plaque and endothe-
ium, thereby potentially mitigating late luminal loss by
alting migration and proliferation of vascular smooth
uscle cells and inflammatory cells through open stent
truts.35 This may result in a reduction of restenosis caused
y luminal encroachment from extracellular matrix deposi-
ion intimal hyperplasia.15,36 BMSs do not provide a
oundary that excludes the underlying plaque from the
umen, and stent oversizing relative to the reference lumen
auses an increase in neointimal growth. Covered stents
ay also offer the benefit of being less thrombogenic than
MSs. In the United States, no covered stents are currently
pproved by the U.S. Food and Drug Administration for
pplication in the iliac arteries for occlusive disease. How-
ver, homemade covered stents, iliac limbs from modular
ortic stent grafts, and commercially manufactured covered
tents approved for other nonvascular indications have
een placed in the iliac arteries. Because of the bulk of the
dditional graft material, covered stents require larger de-
ivery systems than BMSs. This may expose the patient to a
igher risk of groin complications.
The restenosis observed in the covered-stent group was
redominantly located at the ends of the stent or outside
he stent. We hypothesis that this may be secondary to
ompliance mismatch due to the use of the rigid end of the
overed stent and balloon dilatation causing the increased
tent–artery interface intimal hyperplasia. In addition, the
tent may not cover the lesion fully, resulting in progression
f the atherosclerotic process by activation from balloon
nflation but with the end of the balloon inflated firstly
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Volume 54, Number 6 Mwipatayi et al 1569outside of the stent causing a process known as the “dog
bone” effect.
We have identified three major limitations in this study:
First, the different stent types used in the BMS group may
have affected the results and led to bias. It was impractical in
the context of a multicenter study to limit the BMS type.
We suggested current practices and protocols within trial
centers should continue unchanged, with the type of BMS
selected left to the individual operator.
Second, the BMS group had fewer patients with a
TASC D lesion (7%) compared with the covered-stent
group (16.1%), which, despite the randomization, may
have influenced the results.
Third, DUS was the principal imaging tool used for
follow-up, which may have introduced bias because it is
highly operator-dependent. We decided to use DUS imag-
ing because we were reluctant to unnecessarily use invasive
investigations if not clinically required.
CONCLUSIONS
There is increasing evidence from single-center clinical
investigations that patients with complex aortoiliac lesions,
including chronic iliac artery occlusions and occlusion of
the aortoiliac bifurcation, can be treated safely and effec-
tively with a covered stent. The COBEST results demon-
strate that for patients with severe aortoiliac arterial occlu-
sive disease, there is an increased freedom from restenosis
and occlusion with covered stents compared with BMSs at
12 and 18 months. However, long-term durability data
(5-year follow-up) is desirable.
Fig 7. Kaplan-Meier curves for freedom from target ve
reinterventions occurred in the covered-stent group (P
TVR, target vessel revascularization.We thank Dr Michael Phillips for his statistical advice.UTHOR CONTRIBUTIONS
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ement of the bare-metal stent and the covered (V12) stent.
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